| 180 DEGREE CAPITAL CORP. CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2020 (UNAUDITED) | |||||||||||||||||||||||||||||
| Method of Valuation (1) | Industry | Shares/Principal | Cost | Value | |||||||||||||||||||||||||
| Investments in Unaffiliated Companies (2) - | |||||||||||||||||||||||||||||
| 50.9% of net assets at value | |||||||||||||||||||||||||||||
| Privately Held Companies (Illiquid) - | |||||||||||||||||||||||||||||
| 31.4% of net assets at value | |||||||||||||||||||||||||||||
| AgBiome, LLC (3)(4) | Fertilizers & Agricultural Chemicals | ||||||||||||||||||||||||||||
| Providing early-stage research and discovery for agriculture and utilizing the crop microbiome to identify products that reduce risk and improve yield | |||||||||||||||||||||||||||||
| Series A-1 Convertible Preferred Units (acquired 1/30/13) | (I) (L3) | 2,000,000 | $ | 2,000,000 | $ | 10,151,600 | |||||||||||||||||||||||
| Series A-2 Convertible Preferred Units (acquired 4/9/13-10/15/13) | (I) (L3) | 417,392 | 521,740 | 2,156,461 | |||||||||||||||||||||||||
| Series B Convertible Preferred Units (acquired 8/7/15) | (I) (L3) | 160,526 | 500,006 | 937,982 | |||||||||||||||||||||||||
| 3,021,746 | 13,246,043 | ||||||||||||||||||||||||||||
| AutoTech Ventures Management I, LLC (3)(4)(5) | Asset Management & Custody Banks | ||||||||||||||||||||||||||||
| Venture capital investing in automotive-related companies | |||||||||||||||||||||||||||||
| LLC Interests (acquired 12/1/17) | (M) (L3) | 0 | 0 | 125,000 | |||||||||||||||||||||||||
| D-Wave Systems, Inc. (3)(4)(6) | Technology Hardware, Storage & Peripherals | ||||||||||||||||||||||||||||
| Developing high-performance quantum computing systems | |||||||||||||||||||||||||||||
| Series 1 Class B Convertible Preferred Stock (acquired 9/30/08) | (I) (L3) | 1,144,869 | 1,002,074 | 274,360 | |||||||||||||||||||||||||
| Series 1 Class C Convertible Preferred Stock (acquired 9/30/08) | (I) (L3) | 450,450 | 487,804 | 107,947 | |||||||||||||||||||||||||
| Series 1 Class D Convertible Preferred Stock (acquired 9/30/08) | (I) (L3) | 855,131 | 748,473 | 204,926 | |||||||||||||||||||||||||
| Series 1 Class E Convertible Preferred Stock (acquired 11/24/10) | (I) (L3) | 269,280 | 248,049 | 64,531 | |||||||||||||||||||||||||
| Series 1 Class F Convertible Preferred Stock (acquired 11/24/10) | (I) (L3) | 258,721 | 238,323 | 62,001 | |||||||||||||||||||||||||
| Series 1 Class H Convertible Preferred Stock (acquired 6/27/14) | (I) (L3) | 460,866 | 909,088 | 110,443 | |||||||||||||||||||||||||
| Series 2 Class D Convertible Preferred Stock (acquired 9/30/08) | (I) (L3) | 678,264 | 736,019 | 162,541 | |||||||||||||||||||||||||
| Series 2 Class E Convertible Preferred Stock (acquired 6/1/12-3/22/13) | (I) (L3) | 513,900 | 659,493 | 123,153 | |||||||||||||||||||||||||
| Series 2 Class F Convertible Preferred Stock (acquired 6/1/12-3/22/13) | (I) (L3) | 493,747 | 633,631 | 118,323 | |||||||||||||||||||||||||
| 5,662,954 | 1,228,225 | ||||||||||||||||||||||||||||
| 180 DEGREE CAPITAL CORP. CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2020 (UNAUDITED) | |||||||||||||||||||||||||||||
| Method of Valuation (1) | Industry | Shares/Principal | Cost | Value | |||||||||||||||||||||||||
| Investments in Unaffiliated Companies (2) - | |||||||||||||||||||||||||||||
| 50.9% of net assets at value (cont.) | |||||||||||||||||||||||||||||
| Privately Held Companies (Illiquid) - | |||||||||||||||||||||||||||||
| 31.4% of net assets at value (cont.) | |||||||||||||||||||||||||||||
| Fleet Health Alliance, LLC (3)(4) | Health Care Technology | ||||||||||||||||||||||||||||
| Developing software for information transfer amongst healthcare providers and consumers | |||||||||||||||||||||||||||||
| Unsecured Convertible Bridge Note, 0%, (acquired 4/22/16, no maturity date) | (I) (L3) | $ | 225,000 | $ | 225,000 | $ | 0 | ||||||||||||||||||||||
| Lodo Therapeutics Corporation (3) | Pharmaceuticals | ||||||||||||||||||||||||||||
| Developing and commercializing novel therapeutics derived from a metagenome-based Natural Product Discovery Platform | |||||||||||||||||||||||||||||
| Series A Convertible Preferred Stock (acquired 12/21/15-4/22/16) | (I) (L3) | 658,190 | 658,190 | 761,992 | |||||||||||||||||||||||||
| Secured Convertible Bridge Note, 6% PIK, (acquired 6/27/19, maturing 5/7/21) | (M) (L3) | $ | 474,019 | 495,759 | 495,759 | ||||||||||||||||||||||||
| 1,153,949 | 1,257,751 | ||||||||||||||||||||||||||||
| Magnolia Neurosciences Corporation (3)(4) | Pharmaceuticals | ||||||||||||||||||||||||||||
| Developing and commercializing novel therapeutics for treatment of neurodegeneration | |||||||||||||||||||||||||||||
| Series A Convertible Preferred Stock (acquired 8/3/18) | (I) (L3) | 862,872 | 862,872 | 665,841 | |||||||||||||||||||||||||
| Nanosys, Inc. (3)(4) | Specialty Chemicals | ||||||||||||||||||||||||||||
| Developing inorganic nanowires and quantum dots for use in LED-backlit devices | |||||||||||||||||||||||||||||
| Series C Convertible Preferred Stock (acquired 4/10/03) | (I) (L3) | 803,428 | 1,500,000 | 375,882 | |||||||||||||||||||||||||
| Series D Convertible Preferred Stock (acquired 11/7/05) | (I) (L3) | 1,016,950 | 3,000,003 | 800,146 | |||||||||||||||||||||||||
| Series E Convertible Preferred Stock (acquired 8/13/10) | (I) (L3) | 433,688 | 496,573 | 462,327 | |||||||||||||||||||||||||
| 4,996,576 | 1,638,355 | ||||||||||||||||||||||||||||
| NanoTerra, Inc. (3)(4) | Research & Consulting Services | ||||||||||||||||||||||||||||
| Developing surface chemistry and nano-manufacturing solutions | |||||||||||||||||||||||||||||
| Warrants for Common Stock expiring on 2/22/21 (acquired 2/22/11) | (I) (L3) | 4,462 | 69,168 | 0 | |||||||||||||||||||||||||
| Warrants for Series A-3 Preferred Stock expiring on 11/15/22 (acquired 11/15/12) | (I) (L3) | 47,508 | 35,403 | 0 | |||||||||||||||||||||||||
| 104,571 | 0 | ||||||||||||||||||||||||||||
| 180 DEGREE CAPITAL CORP. CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2020 (UNAUDITED) | |||||||||||||||||||||||||||||
| Method of Valuation (1) | Industry | Shares/Principal | Cost | Value | |||||||||||||||||||||||||
| Investments in Unaffiliated Companies (2) - | |||||||||||||||||||||||||||||
| 50.9% of net assets at value (cont.) | |||||||||||||||||||||||||||||
| Privately Held Companies (Illiquid) - | |||||||||||||||||||||||||||||
| 31.4% of net assets at value (cont.) | |||||||||||||||||||||||||||||
| Petra Pharma Corporation (3) | Pharmaceuticals | ||||||||||||||||||||||||||||
| Developing small molecule inhibitors for treatment of cancer and metabolic diseases | |||||||||||||||||||||||||||||
| Series A Convertible Preferred Stock (acquired 12/23/15-1/8/18) | (I) (L3) | 1,894,798 | $ | 1,894,798 | $ | 1,642,681 | |||||||||||||||||||||||
| Secured Convertible Bridge Note, 7% PIK, (acquired 8/30/18, maturing 6/30/20) | (M) (L3) | $ | 369,748 | 410,876 | 308,157 | ||||||||||||||||||||||||
| Secured Convertible Bridge Note, 7% PIK, (acquired 4/11/19, maturing 6/30/20) | (M) (L3) | $ | 116,601 | 124,562 | 93,421 | ||||||||||||||||||||||||
| Secured Convertible Bridge Note, 7% PIK, (acquired 7/18/19, maturing 6/30/20) | (M) (L3) | $ | 143,903 | 151,023 | 113,267 | ||||||||||||||||||||||||
| 2,581,259 | 2,157,526 | ||||||||||||||||||||||||||||
| Phylagen, Inc. (3)(4) | Research & Consulting Services | ||||||||||||||||||||||||||||
| Developing technology to improve human health and business productivity | |||||||||||||||||||||||||||||
| Series A Convertible Preferred Stock (acquired 11/14/18) | (M) (L3) | 548,031 | 233,845 | 374,689 | |||||||||||||||||||||||||
| Total Unaffiliated Privately Held Companies (cost: $18,842,772) | $ | 20,693,430 | |||||||||||||||||||||||||||
| Unaffiliated Publicly Traded Securities - | |||||||||||||||||||||||||||||
| 19.5% of net assets at value | |||||||||||||||||||||||||||||
| Alta Equipment Group, Inc. (4)(7) | Trading Companies & Distributors | ||||||||||||||||||||||||||||
| Operates as an industrial and construction equipment company | |||||||||||||||||||||||||||||
| Common Stock (acquired 2/14/20-3/31/20) (3) | (M) (L1) ( L2) | 495,560 | $ | 4,230,976 | $ | 2,116,041 | |||||||||||||||||||||||
| Warrants for the Purchase of Common Stock expiring 4/8/24 (acquired 2/14/20) (3) | (M) (L2) | 150,000 | 222,879 | 89,805 | |||||||||||||||||||||||||
| 4,453,855 | 2,205,846 | ||||||||||||||||||||||||||||
| Emcore Corporation (4) | Communications Equipment | ||||||||||||||||||||||||||||
| Providing mixed-signal optical products | |||||||||||||||||||||||||||||
| Common Stock (acquired 5/3/18-1/7/20) | (M) (L1) | 154,038 | 705,233 | 345,045 | |||||||||||||||||||||||||
| 180 DEGREE CAPITAL CORP. CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2020 (UNAUDITED) | |||||||||||||||||||||||||||||
| Method of Valuation (1) | Industry | Shares/Principal | Cost | Value | |||||||||||||||||||||||||
| Investments in Unaffiliated Companies (2) - | |||||||||||||||||||||||||||||
| 50.9% of net assets at value (cont.) | |||||||||||||||||||||||||||||
| Unaffiliated Publicly Traded Securities - | |||||||||||||||||||||||||||||
| 19.5% of net assets at value (cont.) | |||||||||||||||||||||||||||||
| Franchise Group, Inc. (3)(4) | Specialized Consumer Services | ||||||||||||||||||||||||||||
| Operates franchised and franchisable businesses | |||||||||||||||||||||||||||||
| Common Stock (acquired 3/12/20) | (M) (L2) | 264,706 | $ | 4,500,002 | $ | 2,229,783 | |||||||||||||||||||||||
| Iteris, Inc. (4) | Electronic Equipment & Instruments | ||||||||||||||||||||||||||||
| Providing applied informatics for transportation and agriculture | |||||||||||||||||||||||||||||
| Common Stock (acquired 1/18/19-11/11/19) | (M) (L1) | 370,600 | 1,620,153 | 1,185,920 | |||||||||||||||||||||||||
| Lantronix, Inc. (4) | Communications Equipment | ||||||||||||||||||||||||||||
| Providing secure data access and management solutions | |||||||||||||||||||||||||||||
| Common Stock (acquired 9/18/18-3/31/20) | (M) (L1) | 1,129,402 | 3,620,895 | 2,207,981 | |||||||||||||||||||||||||
| OpGen, Inc. (4)(8) | Biotechnology | ||||||||||||||||||||||||||||
| Developing tools for genomic sequence assembly and analysis | |||||||||||||||||||||||||||||
| Warrants for the Purchase of Common Stock expiring 5/8/20 (acquired 5/5/15) | (M) (L2) | 602 | 425,579 | 7,318 | |||||||||||||||||||||||||
| Warrants for the Purchase of Common Stock expiring 2/17/25 (acquired 5/5/15) | (I) (L3) | 62 | 785 | 47 | |||||||||||||||||||||||||
| 426,364 | 7,365 | ||||||||||||||||||||||||||||
| Quantum Corporation (4) | Technology Hardware, Storage & Peripherals | ||||||||||||||||||||||||||||
| Providing high-density data storage and high-speed data processing solutions | |||||||||||||||||||||||||||||
| Common Stock (acquired 2/4/19-3/11/20) | (M) (L1) | 1,501,120 | 3,983,228 | 4,428,304 | |||||||||||||||||||||||||
| Miscellaneous Common Stocks (9) | (M) (L1) | 612,472 | 263,907 | ||||||||||||||||||||||||||
| Total Unaffiliated Publicly Traded Securities (cost: $19,922,202) | $ | 12,874,151 | |||||||||||||||||||||||||||
| Total Investments in Unaffiliated Companies (cost: $38,764,974) | $ | 33,567,581 | |||||||||||||||||||||||||||
| 180 DEGREE CAPITAL CORP. CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2020 (UNAUDITED) | |||||||||||||||||||||||||||||
| Method of Valuation (1) | Industry | Shares/Principal | Cost | Value | |||||||||||||||||||||||||
| Investments in Non-Controlled Affiliated Companies (2) - | |||||||||||||||||||||||||||||
| 41.7% of net assets at value | |||||||||||||||||||||||||||||
| Privately Held Companies (Illiquid) - | |||||||||||||||||||||||||||||
| 18.2% of net assets at value | |||||||||||||||||||||||||||||
| ABSMaterials, Inc. (3) | Specialty Chemicals | ||||||||||||||||||||||||||||
| Developing nano-structured absorbent materials for water remediation and consumer applications | |||||||||||||||||||||||||||||
| Series A Convertible Preferred Stock (acquired 2/17/10-10/24/11) | (I) (L3) | 390,000 | $ | 435,000 | $ | 11,980 | |||||||||||||||||||||||
| Series B Convertible Preferred Stock (acquired 11/8/13-6/25/14) | (I) (L3) | 1,037,751 | 1,217,644 | 228,217 | |||||||||||||||||||||||||
| Secured Convertible Bridge Note, 8% PIK, (acquired 1/20/16, maturing 6/30/20) | (M) (L3) | $ | 100,000 | 133,600 | 133,600 | ||||||||||||||||||||||||
| Secured Convertible Bridge Note, 8% PIK, (acquired 3/28/17, maturing 6/30/20) | (M) (L3) | $ | 25,000 | 31,027 | 31,027 | ||||||||||||||||||||||||
| 1,817,271 | 404,824 | ||||||||||||||||||||||||||||
| Black Silicon Holdings, Inc. (3)(4)(10)(11) | Semiconductors | ||||||||||||||||||||||||||||
| Holding company for interest in a company that develops silicon-based optoelectronic products | |||||||||||||||||||||||||||||
| Series A Convertible Preferred Stock (acquired 8/4/15) | (M) (L3) | 233,499 | 750,000 | 0 | |||||||||||||||||||||||||
| Series A-1 Convertible Preferred Stock (acquired 8/4/15) | (M) (L3) | 2,966,667 | 890,000 | 0 | |||||||||||||||||||||||||
| Series A-2 Convertible Preferred Stock (acquired 8/4/15) | (M) (L3) | 4,207,537 | 2,445,000 | 0 | |||||||||||||||||||||||||
| Series B-1 Convertible Preferred Stock (acquired 8/4/15) | (M) (L3) | 1,892,836 | 1,169,561 | 0 | |||||||||||||||||||||||||
| Series C Convertible Preferred Stock (acquired 8/4/15) | (M) (L3) | 1,674,030 | 1,171,316 | 0 | |||||||||||||||||||||||||
| Secured Convertible Bridge Note, 8% PIK, (acquired 8/25/16, maturing 8/4/21) | (M) (L3) | $ | 1,278,453 | 1,444,368 | 241,898 | ||||||||||||||||||||||||
| 7,870,245 | 241,898 | ||||||||||||||||||||||||||||
| EchoPixel, Inc. (3)(4) | Health Care Equipment | ||||||||||||||||||||||||||||
| Developing virtual reality 3-D visualization software for life sciences and health care applications | |||||||||||||||||||||||||||||
| Series Seed Convertible Preferred Stock (acquired 6/21/13-6/30/14) | (I) (L3) | 4,194,630 | 1,250,000 | 534,623 | |||||||||||||||||||||||||
| Series Seed-2 Convertible Preferred Stock (acquired 1/22/16) | (I) (L3) | 1,476,668 | 500,000 | 192,402 | |||||||||||||||||||||||||
| Series A-2 Convertible Preferred Stock (acquired 3/23/17) | (I) (L3) | 1,471,577 | 350,000 | 262,600 | |||||||||||||||||||||||||
| 2,100,000 | 989,625 | ||||||||||||||||||||||||||||
| 180 DEGREE CAPITAL CORP. CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2020 (UNAUDITED) | |||||||||||||||||||||||||||||
| Method of Valuation (1) | Industry | Shares/Principal | Cost | Value | |||||||||||||||||||||||||
| Investments in Non-Controlled Affiliated Companies (2) - | |||||||||||||||||||||||||||||
| 41.7% of net assets at value (cont.) | |||||||||||||||||||||||||||||
| Privately Held Companies (Illiquid) - | |||||||||||||||||||||||||||||
| 18.2% of net assets at value (cont.) | |||||||||||||||||||||||||||||
| Essential Health Solutions, Inc. (3) | Health Care Technology | ||||||||||||||||||||||||||||
| Developing software for information transfer amongst healthcare providers and consumers | |||||||||||||||||||||||||||||
| Common Stock (acquired 11/18/16) | (I) (L3) | 200,000 | $ | 20 | $ | 140,750 | |||||||||||||||||||||||
| Series A Convertible Preferred Stock (acquired 11/18/16) | (I) (L3) | 2,750,000 | 2,750,000 | 2,809,899 | |||||||||||||||||||||||||
| Unsecured Convertible Bridge Note, 8%, (acquired 12/19/18, maturing 12/19/21) | (I) (L3) | $ | 50,000 | 50,000 | 50,000 | ||||||||||||||||||||||||
| 2,800,020 | 3,000,649 | ||||||||||||||||||||||||||||
| HALE.life Corporation (3)(4) | Health Care Technology | ||||||||||||||||||||||||||||
| Developing a platform to facilitate precision health and medicine | |||||||||||||||||||||||||||||
| Common Stock (acquired 3/1/16) | (I) (L3) | 1,000,000 | 10 | 79,025 | |||||||||||||||||||||||||
| Series Seed-1 Convertible Preferred Stock (acquired 3/28/17) | (I) (L3) | 11,000,000 | 1,896,920 | 1,077,030 | |||||||||||||||||||||||||
| Series Seed-2 Convertible Preferred Stock (acquired 12/28/18) | (I) (L3) | 12,083,132 | 2,500,000 | 1,234,162 | |||||||||||||||||||||||||
| 4,396,930 | 2,390,217 | ||||||||||||||||||||||||||||
| ORIG3N, Inc. (3)(4) | Health Care Technology | ||||||||||||||||||||||||||||
| Developing consumer focused genetic tests | |||||||||||||||||||||||||||||
| Series 1 Convertible Preferred Stock (acquired 2/5/15-8/5/15) | (H) (L3) | 1,195,315 | 500,000 | 812,361 | |||||||||||||||||||||||||
| Series A Convertible Preferred Stock (acquired 11/25/15-9/7/16) | (H) (L3) | 1,364,666 | 1,500,000 | 972,879 | |||||||||||||||||||||||||
| Series A-2 Convertible Preferred Stock (acquired 5/11/17-2/8/18) | (H) (L3) | 176,386 | 200,002 | 134,284 | |||||||||||||||||||||||||
| 2,200,002 | 1,919,524 | ||||||||||||||||||||||||||||
| Produced Water Absorbents, Inc. (3)(4)(12)(13) | Oil & Gas Equipment & Services | ||||||||||||||||||||||||||||
| Providing integrated process separation solutions to the global oil and gas industries, enabling onsite treatment of produced and flowback water | |||||||||||||||||||||||||||||
| Common Stock (acquired 4/30/16) | (M) (L3) | 50,243,350 | 7,670,281 | 0 | |||||||||||||||||||||||||
| Warrants for Common Stock expiring upon liquidation event (acquired 4/30/16) | (M) (L3) | 450,000 | 65,250 | 0 | |||||||||||||||||||||||||
| Senior Secured Debt, 15% commencing on 4/1/16, matured on 12/31/19 (acquired 4/1/16) | (M) (L3) | $ | 2,533,766 | 2,533,766 | 0 | ||||||||||||||||||||||||
| 10,269,297 | 0 | ||||||||||||||||||||||||||||
| 180 DEGREE CAPITAL CORP. CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2020 (UNAUDITED) | |||||||||||||||||||||||||||||
| Method of Valuation (1) | Industry | Shares/Principal | Cost | Value | |||||||||||||||||||||||||
| Investments in Non-Controlled Affiliated Companies (2) - | |||||||||||||||||||||||||||||
| 41.7% of net assets at value (cont.) | |||||||||||||||||||||||||||||
| Privately Held Companies (Illiquid) - | |||||||||||||||||||||||||||||
| 18.2% of net assets at value (cont.) | |||||||||||||||||||||||||||||
| TARA Biosystems, Inc. (3)(4) | Life Sciences Tools & Services | ||||||||||||||||||||||||||||
| Developing human tissue models for toxicology and drug discovery applications | |||||||||||||||||||||||||||||
| Common Stock (acquired 8/20/14) | (I) (L3) | 2,000,000 | $ | 20 | $ | 538,304 | |||||||||||||||||||||||
| Series A Convertible Preferred Stock (acquired 3/31/17) | (I) (L3) | 6,878,572 | 2,545,493 | 2,437,477 | |||||||||||||||||||||||||
| Series A-2 Convertible Preferred Stock (acquired 4/18/19) | (I) (L3) | 208,577 | 100,000 | 77,974 | |||||||||||||||||||||||||
| 2,645,513 | 3,053,755 | ||||||||||||||||||||||||||||
| Total Non-Controlled Affiliated Privately Held Companies (cost: $34,099,278) | $ | 12,000,492 | |||||||||||||||||||||||||||
| Non-Controlled Affiliated Publicly Traded Securities - | |||||||||||||||||||||||||||||
| 23.5% of net assets at value | |||||||||||||||||||||||||||||
| Potbelly Corporation (4) | Restaurants | ||||||||||||||||||||||||||||
| Operates a chain of sandwich shops | |||||||||||||||||||||||||||||
| Common Stock (acquired 6/24/19-3/9/20) | (M) (L1) | 1,420,000 | $ | 6,061,816 | $ | 4,387,800 | |||||||||||||||||||||||
| Synacor, Inc. (4)(14) | Application Software | ||||||||||||||||||||||||||||
| Providing technology development, multiplatform services and revenue partner for video, internet and communications providers, device manufacturers, and enterprises | |||||||||||||||||||||||||||||
| Common Stock (acquired 4/6/17-3/11/20) | (M) (L1) | 1,708,501 | 4,474,724 | 1,742,671 | |||||||||||||||||||||||||
| Stock Options for Common Stock Expiring 2/28/29 (acquired 3/1/19) (3)(15) | (I) (L3) | 50,000 | 0 | 28,428 | |||||||||||||||||||||||||
| Stock Options for Common Stock Expiring 5/16/29 (acquired 5/16/19) (3)(15) | (I) (L3) | 15,000 | 0 | 8,760 | |||||||||||||||||||||||||
| Restricted Stock Units (acquired 2/27/20) (3)(15) | (M) (L2) | 12,387 | 0 | 12,635 | |||||||||||||||||||||||||
| 4,474,724 | 1,792,494 | ||||||||||||||||||||||||||||
| 180 DEGREE CAPITAL CORP. CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2020 (UNAUDITED) | |||||||||||||||||||||||||||||
| Method of Valuation (1) | Industry | Shares/Principal | Cost | Value | |||||||||||||||||||||||||
| Investments in Non-Controlled Affiliated Companies (2) - | |||||||||||||||||||||||||||||
| 41.7% of net assets at value (cont.) | |||||||||||||||||||||||||||||
| Non-Controlled Affiliated Publicly Traded Securities - | |||||||||||||||||||||||||||||
| 23.5% of net assets at value (cont.) | |||||||||||||||||||||||||||||
| TheMaven, Inc. (3)(4) | Interactive Media & Services | ||||||||||||||||||||||||||||
| Providing a shared digital publishing, advertising and distribution platform | |||||||||||||||||||||||||||||
| Series H Convertible Preferred Stock (acquired 6/27/19) | (M) (L2) | 1,320 | $ | 2,000,000 | $ | 2,429,008 | |||||||||||||||||||||||
| Series I Convertible Preferred Stock (acquired 6/28/19) | (M) (L2) | 5,000 | 5,000,000 | 6,069,548 | |||||||||||||||||||||||||
| Series J Convertible Preferred Stock (acquired 10/7/19) | (M) (L2) | 1,000 | 1,000,000 | 824,206 | |||||||||||||||||||||||||
| 8,000,000 | 9,322,762 | ||||||||||||||||||||||||||||
| Total Non-Controlled Affiliated Publicly Traded Securities (cost: $18,536,540) | $ | 15,503,056 | |||||||||||||||||||||||||||
| Total Investments in Non-Controlled Affiliated Companies (cost: $52,635,818) | $ | 27,503,548 | |||||||||||||||||||||||||||
| Total Investments in Privately Held Companies and Publicly Traded Securities (cost: $91,400,792) | $ | 61,071,129 | |||||||||||||||||||||||||||
| Investment in Equity Method Privately Held Company (2) - | |||||||||||||||||||||||||||||
| 0.3% of net assets at value | |||||||||||||||||||||||||||||
| Privately Held Company (Illiquid) - | |||||||||||||||||||||||||||||
| 0.3% of net assets at value | |||||||||||||||||||||||||||||
| Accelerator IV-New York Corporation (3)(4) (16) | Research & Consulting Services | ||||||||||||||||||||||||||||
| Identifying and managing emerging biotechnology companies | |||||||||||||||||||||||||||||
| Series A Common Stock (acquired 7/21/14-12/12/18) | (E) | 833,333 | $ | 180,776 | $ | 180,776 | |||||||||||||||||||||||
| Total Investment in Equity Method Privately Held Company (adjusted cost: $180,776) | $ | 180,776 | |||||||||||||||||||||||||||
| Total Investments (cost: $91,581,568) | $ | 61,251,905 | |||||||||||||||||||||||||||
| 180 DEGREE CAPITAL CORP. CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2020 (UNAUDITED) | |||||||||||||||||||||||||||||
| Method of Valuation (1) | Industry | Shares/Principal | Cost | Value | |||||||||||||||||||||||||
| Derivative Investments | |||||||||||||||||||||||||||||
| Unaffiliated Rights to Payments (Illiquid) - | |||||||||||||||||||||||||||||
| 2.7% of net assets at value | |||||||||||||||||||||||||||||